Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Boston Commerce Limited (BOSTONBIO) is currently trading at 6.57 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Boston Bio Systems Limited is primarily engaged in trading medical equipment, testing kits, and instruments. Originally founded in 1995, the company started with share broking and trading in shares and derivatives. The company's shift to trading medical goods suggests a strategic realignment towards the healthcare sector. There is no detailed updated information on its current performance or market position, indicating limited available data.
Over the past 52 weeks, Boston Commerce Limited has traded between a low of ₹5.13 and a high of ₹10.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Boston Commerce Limited has a market capitalization of approximately 4.67. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Boston Commerce Limited’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4.67 Cr, Boston Commerce Limited is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Boston Commerce Limited operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Boston Commerce Limited is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Boston Bio Systems Limited is primarily engaged in trading medical equipment, testing kits, and instruments.
Originally founded in 1995, the company started with share broking and trading in shares and derivatives.
The company's shift to trading medical goods suggests a strategic realignment towards the healthcare sector.
There is no detailed updated information on its current performance or market position, indicating limited available data.
Healthcare Services
Healthcare Service Provider
5 Cr
Low Risk
0.0
59.0
—
0.9
10.95
5.13
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
3
Neutral
3
Bullish
8
Bearish
35
Neutral
3
Bullish
8
Bearish
32
Neutral
0
Bullish
0
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
9.50 | 10 Cr | 452.50 | 0.64 | 0.00 | 0.16 | 0.21 | 0.19 | ||
38.00 | 9 Cr | 20.66 | 0.93 | 0.00 | 4.52 | 6.80 | 3.67 | ||
20.10 | 8 Cr | 20.51 | 0.79 | 0.00 | 3.81 | 3.50 | 2.22 | ||
9.38 | 8 Cr | 131.00 | 0.56 | 0.00 | 4.53 | 3.40 | 0.40 | ||
5.67 | 6 Cr | — | 0.32 | 0.00 | -3.76 | -1.02 | -2.81 | ||
5.00 | 6 Cr | — | 0.54 | 0.00 | -1.16 | 0.77 | -0.80 | ||
6.57 | 5 Cr | — | 0.88 | 0.00 | -10.91 | 0.16 | -7.87 | ||
| Median: 7 Co. | — | 9.38 | 8 Cr | 75.83 | 0.64 | 0.00 | 0.16 | 0.77 | 0.19 |
Capital reduction & asset write‑off
On June 5, 2026 Boston Commerce Ltd.'s Board approved initiating a scheme to confirm and write‑off certain not‑readily‑realisable assets and to initiate a capital reduction scheme, both subject to shareholder and statutory approvals.
Capital reduction & Asset write-off
Board of Boston Commerce Ltd (meeting 5 Jun 2026) approved initiating a scheme to confirm/write-off certain not readily realizable assets and initiated a capital reduction scheme, subject to shareholder and statutory approvals (EGM to be scheduled).
